Cantabio licenses U. Cambridge's tau protein IP for AD
Executive Summary
To develop potential Alzheimer's disease (AD) therapeutics, Cantabio Pharmaceuticals Inc. (formerly Gardedam Therapeutics) licensed a therapeutic program involving the tau protein from the University of Cambridge through its tech transfer arm Cambridge Enterprise Ltd.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice